1. Home
  2. ATNM vs ATCH Comparison

ATNM vs ATCH Comparison

Compare ATNM & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.17

Market Cap

42.0M

Sector

Health Care

ML Signal

HOLD

Logo AtlasClear Holdings Inc.

ATCH

AtlasClear Holdings Inc.

HOLD

Current Price

$0.23

Market Cap

40.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
ATCH
Founded
2000
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.0M
40.1M
IPO Year
2013
2024

Fundamental Metrics

Financial Performance
Metric
ATNM
ATCH
Price
$1.17
$0.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$4.50
$1.00
AVG Volume (30 Days)
108.9K
2.0M
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
N/A
0.05
Revenue
$90,000.00
N/A
Revenue This Year
N/A
$84.47
Revenue Next Year
N/A
$39.32
P/E Ratio
N/A
$4.51
Revenue Growth
11.11
N/A
52 Week Low
$0.95
$0.14
52 Week High
$1.95
$1.92

Technical Indicators

Market Signals
Indicator
ATNM
ATCH
Relative Strength Index (RSI) 45.36 41.51
Support Level $0.99 $0.20
Resistance Level $1.25 $0.24
Average True Range (ATR) 0.07 0.02
MACD -0.01 -0.01
Stochastic Oscillator 8.70 37.38

Price Performance

Historical Comparison
ATNM
ATCH

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About ATCH AtlasClear Holdings Inc.

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

Share on Social Networks: